Journal
CURRENT PROBLEMS IN CARDIOLOGY
Volume 47, Issue 7, Pages -Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.cpcardiol.2021.100956
Keywords
-
Categories
Funding
- Hamad Medical Corporation [MRC-01-20-256]
Ask authors/readers for more resources
This study compared the effectiveness and safety of rosuvastatin and atorvastatin, two high-intensity statins, in patients with acute coronary syndrome. The results showed that there were no significant differences in cardiovascular outcomes and safety between the two drugs at 1 month and 12 months of follow-up.
A high-intensity statin is recommended for the secondary prevention of cardiovascular diseases (CVD). However, real-world evidence of the effectiveness of rosuvastatin following acute coronary syndrome (ACS) is scarce. This retrospective cohort study included patients diagnosed with ACS to compare between the 2 high-intensity statin therapies (rosuvastatin vs atorvastatin) in terms of a primary composite outcome of CVD-associated death, non-fatal ACS, and non-fatal stroke at 1 month and 12 months post discharge. The primary effectiveness outcome did not differ between the 2 groups at 1 month (1.3% vs 1 %; aHR = 1.64, 95% CI 0.55-4.94, P= 0.379) and at 12 months (4.8% vs 3.5%; aHR = 1.48, 95% CI 0.82-2.67, P= 0.199). Similarly, the 2 groups had comparable safety outcomes. In conclusion, the use of high-intensity rosuvastatin compared to high-intensity atorvastatin therapy in patients with ACS had resulted in comparable cardiovascular effectiveness and safety outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available